Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

X4 Pharmaceuticals (XFOR) Non-Current Assets (2018 - 2025)

X4 Pharmaceuticals (XFOR) has disclosed Non-Current Assets for 8 consecutive years, with $30.8 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Non-Current Assets fell 12.62% year-over-year to $30.8 million, compared with a TTM value of $131.6 million through Sep 2025, up 9.26%, and an annual FY2024 reading of $34.3 million, up 36.1% over the prior year.
  • Non-Current Assets was $30.8 million for Q3 2025 at X4 Pharmaceuticals, down from $32.2 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $41.1 million in Q1 2021 and bottomed at $24.8 million in Q1 2024.
  • Average Non-Current Assets over 5 years is $31.1 million, with a median of $29.3 million recorded in 2021.
  • The sharpest move saw Non-Current Assets crashed 30.46% in 2022, then skyrocketed 38.44% in 2024.
  • Year by year, Non-Current Assets stood at $29.3 million in 2021, then decreased by 8.15% to $26.9 million in 2022, then dropped by 6.42% to $25.2 million in 2023, then skyrocketed by 36.1% to $34.3 million in 2024, then fell by 10.28% to $30.8 million in 2025.
  • Business Quant data shows Non-Current Assets for XFOR at $30.8 million in Q3 2025, $32.2 million in Q2 2025, and $34.3 million in Q1 2025.